Image

Sophie van Asten

Associate

Sophie specializes in intellectual property law and advises on (the enforcement of) a wide range of intellectual property matters, with a particular focus on patent litigation.

Her experience includes (cross border) patent enforcement in both the life sciences and tech sector and IP enforcement actions against the sale of parallel imported goods by online platforms.

Sophie works with both national and international clients across jurisdictions and in multiple sectors, including life sciences and TMT.

Experience

Representative matters

An American pharmaceutical company in a revocation action against the EP084 patent acquired by Novartis from Genentech.

An American pharmaceutical company on its (pre-) litigation strategy in light of potential threatened (PI) infringement proceedings in the Netherlands. 

A global pharmaceutical and healthcare company in the enforcement of its patent against Ceva Santé Animale's product for the treatment of coccidiosis / anemia.   

A European pharmaceutical company on its patent (pre-) litigation strategy with respect to the Netherlands.

Pro bono

Launching and leading the Young Apollo Board, representing the younger generation of lawyers at our Amsterdam office and raising awareness within the firm for topics relevant for this target group, such as leadership and personal development.

Ambassador of the Street Child committee in Amsterdam, A&O’s former global charity partner.

Organising fundraising activities for Street Child’s project directed to children in Sierra Leone.

Leadership Positions And Professional Affiliations

Bachelor of Laws, Utrecht University

Master of Laws, Intellectual Property Law, VU University Amsterdam

Exchange, Intellectual Property Law, Case Western Reserve University in Cleveland OH

Disclaimer
A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.